Pauwels Eric 4

What Happened

• Eric Pauwels, Chief Business Officer of PTC Therapeutics (PTCT), exercised 17,566 option shares (cost $18.01 each, total $316,364) on June 10, 2026 and then sold a total of 21,277 common shares that same day (17,566 and 3,711 shares) at $75.00 each for combined proceeds of $1,595,775. The filing also shows a 17,566-share disposition listed at $0 (derivative) in the same reporting set.
• Net of the exercise cost, the transactions generated roughly $1.28M in proceeds (sales of ~$1.60M minus $316k exercise cost). One of the sales was executed pursuant to a written Rule 10b5-1 plan adopted by Pauwels on February 25, 2026.

Key Details

• Transaction date: June 10, 2026; Filing date: June 12, 2026 (filed within the typical two-business-day Form 4 window).
• Sales: 17,566 shares @ $75.00 = $1,317,450; 3,711 shares @ $75.00 = $278,325; total sales ≈ $1,595,775.
• Exercise (acquisition): 17,566 shares @ $18.01 = $316,364.
• Additional entry: 17,566-share disposal shown at $0 labeled as "Derivative" (filing does not explain the zero-price entry).
• Footnotes: F1 — at least one sale was effected under a Rule 10b5-1 plan (adopted Feb 25, 2026). F2 — the exercised options were "currently exercisable."
• Shares owned after the transactions: Not specified in the provided filing details.

Context

• This is effectively a cashless exercise: Pauwels exercised options and sold the same number of shares (17,566) immediately, a common way for insiders to monetize option gains. The extra 3,711 shares sold at $75 appear to be an additional open-market sale (one sale was under a 10b5-1 plan).
• These entries are factual reporting of transactions; they do not by themselves indicate insider sentiment about the company’s future.